American Oriental Bioengineering, Inc. To Announce 2005 Fourth Quarter and Year End Results on March 31, 2006.HONG KONG Hong Kong (hŏng kŏng), Mandarin Xianggang, special administrative region of China, formerly a British crown colony (2005 est. pop. 6,899,000), land area 422 sq mi (1,092 sq km), adjacent to Guangdong prov. -- American Oriental Bioengineering bioengineering Application of engineering principles and equipment to biology and medicine. It includes the development and fabrication of life-support systems for underwater and space exploration, devices for medical treatment (see , Inc. (AMEX AMEX See: American Stock Exchange :AOB AOB (on the agenda for a meeting) any other business ), an emerging Chinese company that produces and distributes a broad range of pharmaceutical and nutraceutical products, announced today it will release its 2005 fourth quarter and year end results before the market opens on Friday, March 31, 2006. After the release, the company will host a conference call to discuss these results. The conference call will take place at 10 a.m. ET. Interested participants should call 877-502-9274 when calling within the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. or 913-981-5584 when calling internationally. There will be a playback available until April 7, 2006. To listen to the playback, please call 888-203-1112 when calling within the United States or 719-457-0820 when calling internationally. Please use pass code 2807144 for the replay. This call is being webcast by ViaVid Broadcasting and can be accessed at American Oriental Bioengineering's web site at http://www.bioaobo.com. The webcast may also be accessed at ViaVid's website at www.viavid.net. The webcast can be accessed until April 30, 2006 on either site. About American Oriental Bioengineering, Inc. American Oriental Bioengineering, Inc. (AOB) uses proprietary processes for producing soybean soybean, soya bean, or soy pea, leguminous plant (Glycine max, G. soja, or Soja max) of the family Leguminosae (pulse family), native to tropical and warm temperate regions of Asia, where it has been protein peptide more efficiently than traditional extracting techniques. These techniques are used to manufacture and formulate supplemental and medicinal products. Soybean peptides are used widely in general food, health food products and medicines, among other applications. AOB also produces Cease-Enuresis Soft Gel, the only Chinese FDA-approved first grade, prescription medicine that is specially formulated to help alleviate bed-wetting and incontinence. The Company is a leading producer of products in both the nutriceuticals and pharmaceuticals areas in China. For more information, visit http://www.bioaobo.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion